Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Earnings and Valuation
This table compares Nektar Therapeutics and Pluri”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nektar Therapeutics | $55.23 million | 23.44 | -$164.08 million | ($6.70) | -5.66 |
| Pluri | $1.02 million | 11.62 | -$23.82 million | ($2.45) | -0.38 |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Nektar Therapeutics and Pluri, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nektar Therapeutics | 1 | 4 | 10 | 1 | 2.69 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
Nektar Therapeutics presently has a consensus price target of $130.67, suggesting a potential upside of 244.59%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Pluri.
Institutional and Insider Ownership
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Nektar Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Profitability
This table compares Nektar Therapeutics and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nektar Therapeutics | -287.84% | -37.87% | -25.67% |
| Pluri | -2,344.59% | N/A | -82.71% |
Summary
Nektar Therapeutics beats Pluri on 10 of the 15 factors compared between the two stocks.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
